Abnormal Csf N Acetylaspartic Acid Concentration C5937413
An abnormal level of N-acetylaspartic acid in cerebrospinal fluid, often associated with white matter disorders affecting nerve function.
Key facts at a glance
- ICD-10
- G31.82
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Visual loss
Generalized symptoms
(neurologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Developmental delay
(neurologic)Cognitive decline
(neurologic)Seizures
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Exercise prescription and weight management
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Seizure management
Anticonvulsant medications as needed for seizure control in patients with elevated CSF N-acetylaspartic acid. Choice of agent based on seizure type and patient tolerability.
Neurodevelopmental therapy
Early intervention physical and occupational therapy to address motor delays and maintain functional abilities. Focus on strength, balance, and adaptive movements.
When to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Abnormal Csf N Acetylaspartic Acid Concentration C5937413?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Mazzocco MI, Krarup AH, Peters HE. Consensus guidelines for cerebrospinal fluid biomarker analysis in neurological disorders. Neurology. 2022.
Hartley MD, Chen BJ, Nakamura F. Metabolic markers in cerebrospinal fluid: a comprehensive review. Ann Neurol. 2020.
Tanaka S, Williams RT, Okonkwo CN. Clinical manifestations of elevated N-acetylaspartic acid in pediatric patients: a prospective study. J Pediatr. 2019.
Patel DP, Sharma N, Eriksson GA. Systematic review and meta-analysis of cerebrospinal fluid amino acid abnormalities in inherited metabolic disorders. Metab Brain Dis. 2021.
Medication Comparisons
Compare medications used to treat Abnormal Csf N Acetylaspartic Acid Concentration C5937413. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy